他克莫司治疗膜性肾病的效果及对患者T淋巴细胞亚群的影响

Abstract
Figure/Table
References (15)
Related Citation (2)

Download: PDF (0 KB) HTML (30 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the effect of Tacrolimus in the treatment of membranous nephropathy and its effect on patients with T lymphocyte subsets.MethodsFrom October 2015 to July 2017,82 patients with membranous nephropathy treated in our hospital were selected as subjects of the study and were divided into two groups according to the random number table method,41 cases in each group.Prednisone was used in all patients.In addition to the control group,the patients were treated with Leflunomide,and the patients in the observation group were treated with Tacrolimus,6 months was one course of treatment.The levels of the 24 h urinary protein,serum creatinine,CD3+,CD4+/CD8+before and after treatment and the total effective of clinical treatment between the two groups were compared.ResultsAfter treatment,the 24 h urinary protein and serum creatinine levels in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).The CD3+and CD4+/CD8+in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).The total effective treatment rate in the observation group(80.49%)was higher than that in the control group(58.54%),and the difference was statistically significant(P＜0.05).ConclusionTacrolimus combined with Prednisone is effective in treating membranous nephropathy,which can improve renal function,regulate immune function,be safe and reliable,and worth promoting.

Key words： Tacrolimus Membranous nephropathy T lymphocyte subsets Renal function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I3/111

[1]	陈超阳，盛晓燕，周颖，等.他克莫司治疗原发性肾病综合征的疗效和安全性的Meta分析[J].中国新药杂志，2015，24（1）：64-73.
[2]	刘书真.环磷酰胺、来氟米特联合泼尼松序贯疗法用于Ⅱ期膜性肾病的临床观察[J].中国药房，2016，27（15）：2040-2042.
[3]	周晓云，周杨.他克莫司单药治疗特发性膜性肾病的近期疗效[J]中国中西医结合肾病杂志，2014，15（8）：706-708.
[4]	段玉静，柴华旗，沙文刚，等.75例特发性膜性肾病临床病理分析[J].安徽医药，2014，18（8）：1530-1532.
[5]	黎磊石，刘志红.中国肾脏病学[M].北京：人民军医出版社，2008：640-645．
[6]	江罗佳，冯益宇，房向东，等.他克莫司与环磷酰胺比较治疗特发性膜性肾病的系统评价[J].实用医学杂志，2014，43（1）：121-126.
[7]	章友康.特发性膜性肾病的诊断治疗进展[J].内科急危重症杂志，2012，18（2）：118-119.
[8]	段玉静，柴华旗，沙文刚，等.75例特发性膜性肾病临床病理分析[J].安徽医药，2014，18（8）：1530-1532.
[9]	李超，管音，李航，等.特发性膜性肾病诊断与治疗的新认识[J].临床内科杂志，2014，31（5）：293-296.
[10]	李艺，王帅，赵景宏，等.他克莫司与环磷酰胺联合激素治疗特发性膜性肾病的疗效比较[J].中国临床药理学与治疗学，2012，17（7）：797-801.
[11]	龙腾翔.特发性膜性肾病外周血淋巴细胞亚群的免疫学研究进展[J].中国临床新医学，2016，9（5）：449-452.
[12]	Cagnoli L，Tabacchi P，Pasquali S，et al.T cell subset alterations in idiopathic glomerulonephritis[J].Clin Exp Immunol，1982，50（1）：70-76．
[13]	王波，刘志红，吴燕，等.特发性膜性肾病患者调节性T细胞和B淋巴细胞的变化及其临床意义[J].肾脏病与透析肾移植杂志，2009，18（4）：322-328．
[14]	侯终君.他克莫司联合糖皮质激素治疗特发性膜性肾病的临床效果[J].中国医药导报，2014，35（31）：69-72.
[15]	常雄.他克莫司或来氟米特联合泼尼松治疗特发性膜性肾病的疗效及安全性对比[J].药物评价研究，2016，39（5）：818-819.